BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets close in 4 hrs 27 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
285.88+0.75 (+0.26%)
As of 11:33AM EST. Market open.
People also watch
CELGGILDREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close285.13
Open285.39
Bid286.00 x 300
Ask286.20 x 100
Day's Range284.27 - 287.59
52 Week Range223.02 - 333.65
Volume405,358
Avg. Volume1,807,442
Market Cap61.74B
Beta0.50
PE Ratio (TTM)16.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 hours ago

    Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer

    A new biotech has launched in Waltham with a management team made up of former Biogen executives and $38 million in financing from Pfizer, former Genzyme CEO Henri Termeer and other prominent investors. Arrakis Therapeutics said it will focus on developing potential treatments for neurology, cancer and rare genetic disorders that target RNA, the all-important molecules that translate the instructions in DNA into proteins in the body. The $38 million Series A financing was led by California venture capital firm Canaan Partners.

  • Here's Why Celgene's Latest Drug Is So Exciting
    Motley Fool4 days ago

    Here's Why Celgene's Latest Drug Is So Exciting

    The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.

  • Did Biogen Inc. Shoot Itself in the Foot?
    Motley Fool5 days ago

    Did Biogen Inc. Shoot Itself in the Foot?

    Biogen's list price for a new rare-disease drug makes it one of the world's most expensive. Was that a mistake?